Post by icemandios on Jun 4, 2018 23:29:42 GMT
TherapeuticsMD to Present at Jefferies 2018 Healthcare Conference
TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, today announced that the company will present at the Jefferies 2018 Healthcare Conference being held on June 5-8, 2018. Chief Executive Officer Robert G. Finizio and Chief Clinical Officer Brian Bernick, M.D. will participate at the conference.
Details for the presentation include:
Conference Jefferies 2018 Healthcare Conference
Date Wednesday, June 6, 2018
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company has recently received FDA approval for TX-004HR, branded as IMVEXXY™ (estradiol vaginal inserts), for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. The company’s late stage clinical pipeline includes TX-001HR for treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause. The company also manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter prenatal vitamins under the vitaMedMD® and BocaGreenMD® brands.
BOCA RATON, Fla.
Details for the presentation include:
Conference Jefferies 2018 Healthcare Conference
Date Wednesday, June 6, 2018
Time 9:00 AM EST
Additionally, a live webcast and replay can be accessed on the company’s website, www.therapeuticsmd.com, on the Home Page or under the “Investors & Media” section.
TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company has recently received FDA approval for TX-004HR, branded as IMVEXXY™ (estradiol vaginal inserts), for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. The company’s late stage clinical pipeline includes TX-001HR for treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause. The company also manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter prenatal vitamins under the vitaMedMD® and BocaGreenMD® brands.